Jennison Associates Files Schedule 13G/A for Pavella Therapeutics
Jennison Associates filed a Schedule 13G/A for Pavella Therapeutics on October 28.
Related stories
Stocks in France Hit 4-week High
FR40 increased to 7981.00 Index Points, the highest since September 2026. Over the past 4 weeks, France Stock Market Index (FR40) gained 0.18%, and in the last 12 months, it decrea
L impact | EQUITY | Oct 29, 2026, 12:56 PM UTC
Chongqing Rural Commercial Bank Q3 Net Profit Rises 12.38% Y/Y
M impact | EQUITY | Oct 29, 2026, 12:56 PM UTC
Suryoday Small Finance Bank Q2 Net Profit 765.5 Million Rupees
M impact | EQUITY | Oct 29, 2026, 12:55 PM UTC
Changchun High-Tech Q3 Net Profit Falls 39.12% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:55 PM UTC
Solink Raises Fresh Funding
M impact | EQUITY | Oct 29, 2026, 12:55 PM UTC
WABI Raises $55 Million at $1.25 Billion Valuation
WABI raised $55 million at a $1.25 billion valuation, following strong early demand.
L impact | EQUITY | Oct 29, 2026, 12:55 PM UTC